Navigation Links
Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
Date:11/14/2007

>

-- Initiation of a program to evaluate RDEA119 in inflammatory diseases;

and

-- Assessing a next-generation MEK inhibitor from our follow-on program in

a first-in-human micro-dosing study.

On September 30, 2007, Ardea had a total of $35.6 million in cash, cash equivalents and short-term investments. Based on current projections, the Company expects cash, cash equivalents, and short-term investments on December 31, 2007 to be approximately $28 million. The Company expects its current cash resources to fund operations through 2008. These projections exclude the potential impact of any future business development or financing activity.

Approximately 11.8 million common equivalent shares were issued and outstanding on September 30, 2007, including 1.6 million common shares underlying outstanding convertible preferred stock.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such for
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Pressure BioSciences, Inc. Issued First Patent in Canada
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Pressure BioSciences, Inc. Provides Corporate Update
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Can economic incentives such as ... members of the public to increase their donations of ... Hopkins Carey Business School Assistant Professor Mario Macis ... a large body of recent research that supports their ... 2013, issue of Science that the World Health Organization ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... , May 23, 2013 BioTrends ... and advisory firms for specialized biopharmaceutical issues, finds ... and infectious disease specialists reported that in the ... (e.g., intentionally delaying treatment) in anticipation of the ... six months ago, when only 6 percent reported ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... signed into law Senate Bill 338, which is designed ... in the way of University of Wisconsin researchers. , ... turn research ideas into potential business opportunities. He said ... faculty and staff try to start businesses based on ...
... San Francisco or Boston, and youre on the verge of investing ... right: The management team is in place, the business plan is ... a lawyer steps into the room, clears her throat and asks ... not write that check, she says, until you learn more about ...
... - Are state government information technology consolidation projects ... Miszewski, the CIO for the State of Wisconsin, has ... are not unusual for large state projects. He has ... government CIOs, but are cost overruns, implementation delays, and ...
Cached Biology Technology:Why repealing the shareholder wage lien law makes sense 2Why repealing the shareholder wage lien law makes sense 3State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
(Date:5/22/2013)... must join together in a major new effort to ... in providing Earth,s people with clean water that looms ... a comment article in the current edition of ... the American Chemical Society (ACS), the world,s largest scientific ... Ph.D., and Jerald L. Schnoor, Ph.D., explain that shortages ...
(Date:5/22/2013)... The discovery of potential environmental and human health ... batteries each year has led scientists to recommend ... reuse of lithium-ion (Li-ion) battery materials. That,s the ... journal Environmental Science & Technology . , ... Li-ion batteries have become mainstays for powering everything ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... , Research collaboration between India and Germany has intensified. ... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), during a ... research institutes in New Delhi on Nov. 3 and ... countries has reached a new dimension," said the DFG ...
... prey are conservationally at risk, it can be difficult to find ... , Such is the case for a particular population of orcas ... the coast of Washington State and British Columbia, but a new ... what must be done to conserve both. The study, reported ...
... research team at the National Institute of Standards and Technology ... that may play a critical role in the reproduction of ... the "fish flu." A scourge in fish farms with a ... found in wild salmon in the Pacific Northwest for the ...
Cached Biology News:Scientific collaboration between India and Germany reaches new dimension 2Fish flu: Genetics approach may lead to treatment 2
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... regulator and pressurized syringe holder for any researcher ... flow rate Microinjecting Fine microliter delivery ... added to any new or existing perfusion rig ... homemade. Connect to house air or a compressor ...
...
Biology Products: